Clinical trial
ctDNA-MRD and Imaging Response-Guided Adaptive Escalation of Neoadjuvant Therapy in Resectable and Borderline Resectable Non-Small Cell Lung Cancer: A Single-Arm, Proof-of-Concept Study
NCT07885709 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- ctDNA-MRD and Imaging Response-Guided Adaptive Escalation of Neoadjuvant Therapy in Resectable and Borderline Resectable Non-Small Cell Lung Cancer: A Single-Arm, Proof-of-Concept Study
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- August 1, 2030
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer (nsclc)
Arms
As registered; 1 arm.
-
ctDNA-MRD and imaging-guided dynamic neoadjuvant therapy
All participants initially receive two 21-day cycles of one PD-1 inhibitor (nivolumab, pembrolizumab, toripalimab, or tislelizumab) plus platinum-based doublet chemotherapy (nab-paclitaxel/carboplatin for squamous; pemetrexed/carboplatin for non-squamous histology). After two cycles, ctDNA-MRD testing and radiological assessment (RECIST 1.1) guide treatment: patients with ctDNA non-clearance and stable disease receive an intensified four-drug regimen (PD-1 inhibitor + anlotinib + nab-paclitaxel + carboplatin) for cycles 3-4, non-squamous patients switching from pemetrexed to nab-paclitaxel; all others (ctDNA clearance, or CR/PR) continue the original regimen. Upon completion of neoadjuvant therapy, patients deemed resectable by a multidisciplinary team undergo definitive surgery.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Pathological complete response (pCR) rate in the treatment-escalation population
pCR is defined as the absence of residual viable tumor cells in the primary lung tumor and all sampled regional lymph nodes upon systematic pathological review of the surgical specimen, per the IASLC 2020 pathological evaluation criteria. The treatment-escalation population comprises patients with ctDNA non-clearance and radiological stable disease (SD) after two cycles of neoadjuvant therapy.
Lead sponsor's other trials
Peking University People's Hospital, most recent start first.
+604 more trials See the organization page
Similar trials
Same condition (Neoplasm, Residual) and phase, most recent start first.
+82 more trials See the condition page